A retrospective cohort study suggested that colchicine prophylaxis at urate-lowering therapy initiation may lower cardiovascular event risk in patients with gout.
A study assesses whether the dual sodium–glucose co-transporter (SGLT) 1/2 inhibitor sotagliflozin reduces ischemic events in diabetes and kidney disease.
The FDA has proposed new draft guidance to improve the accuracy of pulse oximeters across all skin tones, addressing long-standing concerns about potential disparities in performance.
Acoramidis, an oral therapy, is now approved to reduce cardiovascular-related deaths and hospitalizations in adults with hereditary or wild-type ATTR-CM.
A recent randomized clinical trial demonstrated that a nurse and social worker-led palliative telecare intervention improved quality of life, mental health, and disease-specific outcomes for patients with...
This COVID-19 roundup includes coverage on the latest estimated number of adults with long COVID, WHO’s updated terminology for pathogens that transmit through the air, how COVID-19 vaccination reduces the...
Researchers compared the rates of elective vs emergency surgery for patients living in primary care shortage areas who had one of three access-sensitive surgical conditions.
Researchers compared the effects of once-weekly semaglutide (2.4 mg) with a placebo during a 52-week period in patients with HFpEF and a BMI of 30 or higher.
Researchers investigated the association and the potential sex differences between hypertension and blood pressure in early adulthood (ages 30-40 years) with late-life brain health.
Researchers set out to determine the percentage of people in the United States with type 2 diabetes who meet the recommended criteria to use GLP-1 receptor agonists and SGLT-2 inhibitors as well as patients...
